Long-term platinum retention after treatment with cisplatin and oxaliplatin by Brouwers, Elke EM et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Clinical Pharmacology
Open Access Research article
Long-term platinum retention after treatment with cisplatin and 
oxaliplatin
Elke EM Brouwers*1, Alwin DR Huitema1, Jos H Beijnen1,2 and 
J a nH MS c h e l l e n s 2,3
Address: 1Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, 
The Netherlands, 2Beta faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Section of Drug Toxicology, Utrecht 
University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands and 3Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The 
Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Email: Elke EM Brouwers* - Elke.Brouwers@slz.nl; Alwin DR Huitema - Alwin.Huitema@slz.nl; Jos H Beijnen - Jos.Beijnen@slz.nl; 
Jan HM Schellens - J.schellens@nki.nl
* Corresponding author    
Abstract
Background: The aim of this study was to evaluate long-term platinum retention in patients
treated with cisplatin and oxaliplatin.
Methods: 45 patients, treated 8–75 months before participating in this study, were included.
Platinum levels in plasma and plasma ultrafiltrate (pUF) were determined. In addition, the reactivity
of platinum species in pUF was evaluated. Relationships between platinum retention and possible
determinants were evaluated.
Results: Platinum plasma concentrations ranged between 142–2.99 × 103 ng/L. Up to 24% of
plasma platinum was recovered in pUF. No platinum-DNA adducts in peripheral blood
mononuclear cells (PBMCs) could be detected. Ex vivo incubation of DNA with pUF of patients
revealed that up to 10% of the reactivity of platinum species was retained. Protein binding
proceeded during sample storage. Sodium thiosulfate (STS) appeared to release platinum from the
plasma proteins. Platinum levels were related to time, dose, STS co-administration, and glomerular
filtration rates (GFR).
Conclusion: Our data suggest that plasma platinum levels are related to time, age, dose, GFR, and
STS use. Platinum in plasma, probably, represent platinum eliminated from regenerating tissue.
Platinum species in pUF were partly present in a reactive form. The effects of the reactivity on long-
term consequences of Pt-containing chemotherapy, however, remains to be established.
Background
Since its discovery as an effective anticancer agent in the
1960s [1], cisplatin is used extensively in oncology. The
use of platinum (Pt) agents has had an enormous impact
on the prognosis of several cancer types. After the intro-
duction of cisplatin, mortality of e.g. testicular cancer
reduced significantly. Also oxaliplatin has found a wide-
spread use in the treatment of cisplatin resistant colorectal
cancer [2].
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The improved life expectancy of cancer patients treated
with Pt-based compounds, has led to an increased interest
in the long-term side effects of these drugs, such as periph-
eral neuropathy, nephrotoxicity, and ototoxicity [3-6].
The presence of long-term side effects has led to the inves-
tigation of long-term pharmacokinetics, distribution, and
elimination of Pt-based drugs. Studies have shown that
with a standard cisplatin-containing chemotherapy,
plasma and tissue Pt levels are still remarkably elevated
years after chemotherapy [7-12]. For oxaliplatin, no data
on long-term pharmacokinetics are available yet. In addi-
tion, no studies have been performed to investigate the
potential reactivity of retained Pt species years after treat-
ment.
In the current study the long-term Pt retention in plasma
and plasma ultrafiltrate (pUF) of patients treated with cis-
platin or oxaliplatin up to 6 years before participating in
this study was investigated. The in vivo reactivity of circu-
lating Pt was studied by testing the DNA- and protein
binding activity of ultrafilterable Pt and the ability of
sodium thiosulfate (STS) to release Pt from the plasma
proteins. For quantification of Pt levels in plasma, pUF,
and for quantification of the level of Pt-DNA adducts, we
used inductively coupled plasma mass spectrometry (ICP-
MS). Finally, potential relationships between Pt exposure
and follow-up time, age, cumulative dose, route of admin-
istration, renal function, glutathione S-transferase (GST)
genotypes, and co-administration of STS with intra-arte-
rial cisplatin were investigated.
Methods
Participants
For cisplatin, patients were selected at random from all
patients who started treatment between 2000 and 2004,
received cumulative cisplatin doses of ≥ 300 mg/m2, and
were available for follow-up. This was done to obtain a
heterogeneous sample from the population of patients
treated with cisplatin. For this pilot study, 20 patients of
the 400 eligible patients were included. To select the
patients, random selections were performed on the 400
eligible patients until 20 patients agreed to participate in
the study. SPSS (SPSSinc, version 11.0, Chicago, IL, USA)
was used for random sample selection. Unfortunately, for
oxaliplatin, no random selection could be performed
because, the number of available patients was too low.
This was due to a high mortality rate of the patients
treated with oxaliplatin. Therefore, for oxaliplatin, all
available patients who started treatment between 2000
and 2005 and received cumulative oxaliplatin doses of ≥
600 mg/m2 were approached for participation in the cur-
rent study. This led to an inclusion of 25 patients. The
Medical Ethics Committee of the hospital approved the
study protocol and all patients gave their written
informed consent.
Additionally, 20 cancer patients who were not treated
with cisplatin and 20 healthy volunteers, were included as
a control for Pt background levels in plasma.
Blood sampling
Whole blood samples for Pt analysis were collected in 10
mL EDTA containing tubes (Becton Dickinson Vacutainer
Systems, Plymouth, UK). EDTA was preferred above
heparin because the fraction peripheral blood mononu-
clear cells (PBMCs) could be isolated easier from EDTA
plasma. No difference in the ultrafiltrable fraction was
observed between EDTA or heparin containing tubes.
Plasma was obtained by centrifuging the whole blood
samples for 15 min (1,000 g, 4°C). The fraction contain-
ing PBMCs was isolated from the whole blood sample
using the method described by Pluim et al [13]. PUF was
obtained by centrifuging the plasma fraction through 3
and 30 kDa cut-off ultrafiltrate filter (Centriplus Millipore
Corporation, Bedford, MA, USA) for 30 min (1,000 g,
20°C). Additionally, from each patient, 5 ml blood sam-
ples were obtained for genetic analysis. Lymphocyte DNA
was isolated according to the method of Boom [14]. All
samples were stored at -20°C until analysis.
Determination of Pt levels
Pt analyses were performed using an ICP-MS and a vali-
dated method described previously [15]. Pt levels were
assessed in plasma, pUF, and bound to DNA in PBMCs.
DNA was isolated from PBMCs using a method described
by Pluim et al [13]. Before ICP-MS analysis, the DNA was
hydrolysed in 1% (v/v) HNO3 solution at 70°C. The limit
of quantification (LLOQ) of the method was 20 ng/L for
plasma, 7.5 ng/L for pUF, and the absolute sensitivity for
Pt bound to DNA was 0.75 pg Pt (7.5 fg Pt per μg DNA
when using 100 μg DNA). The LLOQs were determined
on the basis of five times the noise in blank matrix solu-
tions.
Assessment of DNA binding activity of Pt in pUF
PUF samples (500 μL) which contained high Pt concen-
trations of two cisplatin and two oxaliplatin treated
patients, were incubated with an excess of calf thymus
DNA (500 μg) (Sigma-Aldrich) to allow maximal bind-
ing. Additionally, pUF from healthy volunteers was incu-
bated with 500 μg of calf thymus DNA and cisplatin or
oxaliplatin with Pt concentrations equivalent to the inves-
tigated patients samples. The latter was done to assess the
binding capacity of the parent compounds at concentra-
tions in the same range as the patients samples. After a
five-day incubation to achieve a maximal Pt-DNA bind-
ing, the DNA was precipitated, washed and dissolved in
water as described by Brouwers et al [16]. After hydrolysis,
the Pt-DNA binding was assessed.BMC Clinical Pharmacology 2008, 8:7 http://www.biomedcentral.com/1472-6904/8/7
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Ex vivo assessment of protein binding capacity of Pt in pUF
To assess the protein binding capacity of Pt, pUF was pre-
pared for four cisplatin and oxaliplatin plasma samples
after storage at -30°C for 144–278 days. Pt concentrations
analysed in pUF prepared after storage were compared to
Pt concentrations analysed in pUF which was prepared
immediately after blood sampling. Additionally, plasma
samples were reanalyzed to assess whether or not Pt con-
centrations in plasma were reduced during storage due to
adsorption to the tubes.
Ex vivo activity of STS
Four plasma samples for both cisplatin and oxaliplatin
were used to investigate the ability of STS to remove Pt
from proteins. Therefore, 750 μL of plasma were incu-
bated with 25 μL of a 250 g/L STS solution. As control,
750 μL of plasma were incubated with 25 μL of water.
After incubation, pUF was prepared and Pt concentrations
of the STS incubated samples and control samples were
compared. Protein concentrations in the ultrafiltrates
were analysed using a 2-D Quant Kit (GE healthcare Bio-
Sciences AB, Uppsala, Sweden).
Two pUF samples (500 μL) which contained high Pt con-
centrations of one cisplatin and one oxaliplatin treated
patient, were incubated with an excess of calf thymus
DNA (500 μg) (Sigma-Aldrich) in duplicate. Pt-DNA
binding was analysed with and without incubation of STS.
Genotyping
Polymorphisms in the genes encoding the enzymes
GSTM1, GSTT1, and GSTP1 were determined. In GSTT1
and GSTM1, known inherited homozygous deletions are
equivalent to nonfunctional enzymes [17]. In the GSTP1
gene, a functional SNP between adenosine (A) and gua-
nosine (G) at base pair 313 leads to the expression of
either Ile or Val at codon 105. This polymorphism signif-
icantly affects enzyme activity [18].
GSTM1 and GSTT1 deletions were analysed using a gel
electrophoresis method as described by Sreelekha et al
[19]. GSTP1 (exon 5) was genotyped according to Jeróni-
mo et al [20].
Clinical parameters
Information regarding cumulative cisplatin and oxalipla-
tin dose, follow-up time (time since end of treatment),
route of Pt administration, co-administration of STS, and
serum creatinine before start of chemotherapy were col-
lected from patient files. Additionally, serum creatinine
was assessed at the time of study.
Statistical analyses
Differences between Pt levels of cisplatin and oxaliplatin
treated patients, control cancer patients, and healthy con-
trols were evaluated using the Mann-Whitney U test. The
Wilcoxon signed rank test was used to test the difference
between the renal function at the time of chemotherapy
and at follow-up. Correlations between plasma and pUF
level of Pt treated patients were evaluated by the Pearson
correlation coefficient. SPSS was used to perform these
tests.
Possible relationships between determinants and Pt levels
were evaluated using non-linear mixed effects modeling
using NONMEM software (Version V1) (GloboMax LLC,
Ellicott city, MD, USA). The first order conditional estima-
tion method was used throughout. It was assumed that,
due to the long follow-up, the treatment period was neg-
ligible compared to the follow-up time. The significance
of established relationships was assessed using the likeli-
hood ratio test.
Results
Participants
Table 1 summarizes the characteristics of the participants.
Participants were treated with cisplatin for diverse tumour
types, whereas all patients treated with oxaliplatin were
diagnosed with colorectal cancer. The range in the follow-
up time of patients was between 8 and 75 months.
Pt levels
Figure 1 shows Pt levels in plasma of 20 healthy controls,
20 cancer control patients, 20 cisplatin treated cancer
patients treated 18–75 months before entering this study,
and 25 oxaliplatin treated cancer patients treated 8–33
months before entering this study. Moreover, pUF levels
from Pt treated patients are shown. All plasma and pUF
samples of the Pt treated patients were above the LLOQ of
the method (plasma: 142–2.99 × 103 ng/L median 647
ng/L, pUF: 15.3–565 ng/L, median 157 ng/L), whereas
only three plasma samples of control patients exceeded
the LLOQ (plasma: < LLOQ-55.6 ng/L). Pt concentrations
in plasma of Pt treated patients were significantly higher
than those in control patients (Mann-Whitney U test, p <
0.0001). Pt levels in pUF were highly correlated to levels
in plasma. The Pearson correlation coefficients were 0.97
and 0.95 for cisplatin and oxaliplatin respectively. For cis-
platin, on average 14.8% of plasma Pt was recovered in
pUF. This percentage was 24.2% for oxaliplatin. The per-
centage of Pt in pUF was not dependent on the amount of
Pt in plasma. No difference was observed between 3 and
30 kDa filters. Levels of Pt-DNA adducts in PBMCs were
below LLOQ of 0.75 pg Pt in all samples.
Assessment of DNA binding activity of Pt in pUF
Cisplatin and oxaliplatin added to pUF and incubated ex
vivo with DNA revealed that after five days, for both com-
pounds, 21% of the added Pt was bound to DNA. The pUF
samples of the cisplatin patients demonstrated a DNABMC Clinical Pharmacology 2008, 8:7 http://www.biomedcentral.com/1472-6904/8/7
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binding of 1.8 and 2.4%. For oxaliplatin, these percent-
ages were 0.78 and 1.1%. Hence, the experiment showed
that for cisplatin and oxaliplatin, on average, respectively
10 and 4.3% of the total binding capacity of equivalent
concentrations of parent compound was recovered more
than 8 months after the end of treatment. Pt contents of
the DNA samples incubated with the patient samples were
just above the LLOQ of the method (2.1–6.0 pg).
Ex vivo assessment of protein binding capacity of Pt in pUF
Table 2 shows the results of the experiments in which the
plasma protein binding capacity of Pt in plasma samples
of patients was investigated. On average, the decrease in Pt
concentrations in pUF was 45% and 26% for cisplatin and
oxaliplatin, respectively after storage for 144–278 days.
For both compounds, plasma Pt concentrations remained
constant over time.
Ex vivo activity of STS
The results for the Pt concentrations in pUF samples with
and without prior addition of STS to plasma are depicted
in Table 3. For cisplatin and oxaliplatin, respectively, a
2.3- and 1.6-fold increase in Pt pUF concentrations was
observed in samples prepared from STS treated plasma.
No proteins could be detected in any of the pUF samples.
The effect of STS on the Pt-DNA binding in the pUF sam-
ples could not be established.
Effects of determinants on in vivo plasma Pt levels
Plasma Pt levels showed a gradual decline over follow-up
time (Figure 2). The decrease of the Pt levels followed a
first order elimination profile. The elimination profiles
could be desribed by two-compartment models for both
compounds. Two-compartment models were superior to
one compartment models. The first elimination half-life
(t1/2) for cisplatin was 5.02 months and the second 37.0
months. For oxaliplatin, these half-lifes were 1.37 and
535 months. The values of the first phase of cisplatin and
the second phase of oxaliplatin, however, had relatively
high standard errors. Because of the observed overlap of
follow-up time for cisplatin and oxaliplatin (18–75
months vs 8–23 months) the data were also combined.
The combined elimination profile could be described by
a two-compartment model of which the first elimination
half-life (t1/2) was 1.2 months and the second t1/2 28.5
months. The second t1/2 was related to age, in which a two-
fold increase in age resulted in a 1.4-fold longer t1/2 (p =
0.002). Combination of the data led to more reliable
parameter estimates of the two compartment model
because the time window was larger compared to the
analyses of the compounds separately. Evidently, we
should take into account that the first half life was mostly
determined by oxaliplatin data and the second half life
was mostly determined by cisplatin data.
Pt levels were proportional to the cumulative dose. STS
co-adminstration in combination with intra-arterial cispl-
atin administration led to a 71% reduction in Pt levels (p
< 0.001). An association between GSTT1,GSTM1, and
GSTP1 genotypes and Pt levels could not be established.
The effect of the renal function on Pt levels was evaluated
using the glomerular filtration rate (GFR) which was cal-
culated with the 'Modification of Diet in Renal Disease
Table 1: Characteristics of participants
Cisplatin Oxaliplatin
Gender (m/f) 13 m/7 f 20 m/5 f
Age at time of follow-up (median) 49 years 64 years
Duration of follow-up 18–75 months (median 41) 8–33 months (median 18)
Tumour type Testicular carcinoma (9) Colorectal carcinoma (25)
Yolk sac carcinoma (1)
Non small cell lung cancer (1)
Small cell lung cancer (1)
Head and neck carcinoma (8)
Cumulative dose 300–600 mg/m2 cisplatin (median 350) 585–1170 mg/m2 oxaliplatin (median 878)
195–390 mg/m2 Pt 287–575 mg/m2 Pt
(median 227) (median 431)
Sodium thiosulfate 5 head and neck carcinoma patients treated intra-arterially with 
600 mg/m2 cisplatin
NA
Ca/Mg infusion NA 24/25
GSTM1 8/20 positive, 12/20 negative 10/25 positive, 15/25 negative
GSTT1 17/20 wildtype, 3/20 negative 21/25 positive, 4/25 negative
GSTP1 12/20105Ile/105Ile-GSTP1 9/25105Ile/105Ile-GSTP1
7/20105Val/105Ile-GSTP1 10/25105Val/105Ile-GSTP1
1/20105Val/105Val-GSTP1 6/25105Val/105Val-GSTP1
NA = not applicableBMC Clinical Pharmacology 2008, 8:7 http://www.biomedcentral.com/1472-6904/8/7
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(MDRD)'-formula [21]. Median GFR values before start of
the Pt chemotherapy were 78 and 65 mL/min/1.73 m2 for
cisplatin and oxaliplatin, respectively. At the time of the
current study, GFR values of cisplatin patients were signif-
icantly decreased to 55 mL/min/1.73 m2 (p < 0.001),
whereas GFR values for oxaliplatin patients remained con-
stant (61 mL/min/1.73 m2). Figure 3 and 4 show the
MDRD GFR for patients at the start of their chemotherapy
treatment and at follow-up. The GFR at the time of chem-
otherapy was significantly and conversely related to
plasma Pt levels (p < 0.01). Long-term plasma Pt concen-
trations were lower when the GFR at the time of chemo-
therapy was higher.
Discussion
Since the discovery of the antineoplastic effects of Pt-
based compounds, cisplatin and later oxaliplatin have
developed into commonly used anticancer agents. The
Pt concentrations of 20 healthy controls (plasma ), 20 cancer control patients (plasma ■), 20 cancer patients who were  treated with cisplatin 18–73 months before entering this study (plasma ▲ and pUF ), 25 cancer patients who were treated  with oxaliplatin 8–23 months before entering this study (plasma ● and pUF ❍) Figure 1
Pt concentrations of 20 healthy controls (plasma ), 20 cancer control patients (plasma ■), 20 cancer patients 
who were treated with cisplatin 18–73 months before entering this study (plasma ▲ and pUF ), 25 cancer 
patients who were treated with oxaliplatin 8–23 months before entering this study (plasma ● and pUF ❍).
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Table 2: Pt concentrations in eight pUF samples before and after storage
Compound Percentage of plasma Pt recovered in pUF 
before storage
Percentage of plasma Pt recovered in pUF 
after storage
Days of storage
Cisplatin 19.4 8.1 278
19.7 8.4 278
15.1 5.5 276
12.3 7.4 276
Oxaliplatin 27.8 21.2 180
25.9 16 161
22.9 15.8 157
28.2 25.2 144BMC Clinical Pharmacology 2008, 8:7 http://www.biomedcentral.com/1472-6904/8/7
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increased survival of patients treated with these agents
and the associated long-term side effects, have initiated
the investigation of the long-term pharmacokinetics, dis-
tribution, and elimination of Pt-based compounds.
The current study focussed on the long-term pharmacoki-
netics of cisplatin and oxaliplatin in plasma and pUF. We
showed that plasma Pt levels of patients, treated with cis-
platin or oxaliplatin 8 to 75 months before participating
in the current study, were > 30-fold higher than the mean
level of unexposed controls. In earlier studies raised
plasma or serum Pt levels until 240 months after treat-
ment with cisplatin were also reported [7,8,10,11].
In addition to elevated plasma Pt levels, the ultrafiltrable
fraction of the plasma also contained Pt species. This has
not been reported before. The fraction of plasma Pt recov-
ered in the pUF was higher for oxaliplatin than for cispla-
tin, which could be a result of a higher reactivity of
cisplatin and hence, a more extensive protein binding of
Table 3: Pt concentrations in eight pUF samples with and without incubation with STS
Compound Percentage of plasma Pt 
recovered in pUF
Percentage of plasma Pt recovered in pUF 
after STS incubation
Factor increase of Pt in pUF after 
STS incubation
Cisplatin 12.4 17.5 1.4-fold
12.7 34.9 2.7-fold
13.2 30.7 2.3-fold
12.5 36.6 2.9-fold
Oxaliplatin 32.2 46.2 1.4-fold
20 39.5 2.0-fold
26.5 38.7 1.5-fold
27.2 40.4 1.5-fold
Plasma Pt concentrations versus time since end of treatment Figure 2
Plasma Pt concentrations versus time since end of treatment.
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cisplatin. Because pUF is generally considered to contain
the pharmacologically active Pt fraction [22] and inactive
species [23], the question arises as to whether ultrafiltra-
ble Pt measured up to 75 months after chemotherapy is
composed exclusively of inactive Pt bound to low-molec-
ular-weight molecules smaller than 3 kDa, or whether it
might also contain bound or unbound Pt with retained
reactivity. Because ICP-MS can not distinguish between
unchanged cisplatin/oxaliplatin and its metabolites or
adducts, no information on the composition of the Pt spe-
cies in the pUF samples could be obtained. Unfortunately,
up to now, no other technique is sensitive enough to elu-
cidate the chemical composition of the pool of Pt metab-
olites and adducts that are probably present in the pUF
samples.
Therefore, to address the question whether the Pt present
in the pUF samples was still reactive, we attempted to
assess the Pt-DNA binding activity in vivo and ex vivo. We
were not able to quantify Pt-DNA adduct levels in PBMCs
of the patients. This observation, however, does not mean
that there are no Pt-DNA adducts present. The Pt concen-
trations in pUF were only 2 to 75 fold higher than the
LLOQ in this matrix. Therefore, Pt-DNA adduct levels in
PBMCs might well be under the LLOQ of the method of
7.5 fg Pt/μg DNA [16]. Although we were not able to
quantify Pt-DNA adduct levels in vivo, we did show that
for the highest concentrated cisplatin and oxaliplatin
patient pUF samples, respectively 10% and 4.3% of the
DNA binding activity of the parent compound was
retained. The difference between the reactivity of cisplatin
and oxaliplatin samples is in agreement with the differ-
ence in DNA binding activity of the parent compounds.
[24,25]. Whether the Pt-DNA adducts are similar to the
adducts formed by the parent compounds remains to be
established. Unfortunately, the DNA binding activity
could only be evaluated in the highest concentrated pUF
samples. It is relevant to consider that these samples
might not be representative for all pUF samples.
In addition to the remaining DNA binding properties, Pt
in plasma also appeared to have remaining protein bind-
ing capacity, which substantiates the observations that Pt
species recovered years after treatment may still show
reactivity. The reduction in ultrafilterable Pt of 45% and
26% for cisplatin and oxaliplatin, respectively after stor-
age for 144–278 days was less than the reduction
observed by Erkmen et al. [26] for carboplatin after stor-
GFR values for cisplatin treated patients at time of treatment (t = 0) and at follow-up Figure 3
GFR values for cisplatin treated patients at time of treatment (t = 0) and at follow-up.
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age for 100 days. This difference might be caused by the
difference in Pt concentration of the samples (ng/L in the
current study, versus mg/L in the study described by Erk-
men et al.) or by the difference in storage temperature (-
30°C for the current study, versus -20°C in the study
described by Erkmen et al.). Furthermore, the samples of
Erkmen were incubated in vitro with carboplatin, whereas
the samples of the current study were obtained from
patients up to years after treatment. The activity of the cir-
culating Pt, therefore, might be lower in the current sam-
ple set, leading to less reduction of Pt in pUF after storage.
The investigation of the Pt levels in pUF after the ex vivo
incubation of plasma with STS revealed that STS incuba-
tion resulted in higher Pt levels in pUF. This suggests that
at least part of the Pt protein binding is not irreversible
and that a nucleophilic compound such as STS is capable
of releasing Pt from proteins because the nucleophilic
sulfide group, possibly, has a higher binding affinity for Pt
than proteins do. This observation, however, should be
interpreted with caution because the effect of STS on pro-
tein structure and thus of the ability of the proteins to pass
the ultrafiltration membrane could not be evaluated
because protein concentrations in pUF were too low to be
detected. The effect of STS on the Pt-DNA adducts, could
not be established.
Investigation of the effects of determinants on plasma Pt
levels revealed a strong relationship between Pt levels and
the follow-up time. The relationship suggested that
plasma Pt was eliminated according to a first order elimi-
nation profile, of which the first t1/2 (1.2 months) could
be estimated accurately for oxaliplatin and the second t1/2
(28.5 months) could be estimated for cisplatin. For cispl-
atin, associations between plasma Pt levels and follow-up
time were published before [7-11]. Hohnloser et al.
reported an elimination half-life of 6.6 months for the
time segment of 5.4 to 32 months and 26 months for the
time segment of 21 to 107 months [11]. The last t1/2 is in
agreement with our findings. Although the two elimina-
tion half-lives found in this study characterize the data
between 8 and 75 months after the end of treatment, the
complete elimination of plasma Pt can presumably be
described by numerous half-lives which increase with a
longer follow-up period. This was confirmed by investiga-
tions of Gelevert et al., who calculated a t1/2 of 54 months
for patients who were treated with cisplatin 120 to 240
months before follow-up.
GFR values for oxaliplatin treated patients at time of treatment (t = 0) and at follow-up Figure 4
GFR values for oxaliplatin treated patients at time of treatment (t = 0) and at follow-up.
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The long-term Pt plasma levels are, most probably, a
result of Pt accumulation which is released into the blood-
stream due to regeneration of tissue. Several investigations
have shown raised Pt levels in tissue samples up to years
after chemotherapy [27,28]. The two compartments in the
Pt elimination observed in this study, could be explained
by the Pt release from fast regenerating tissue, followed by
a release from slower regenerating tissue. This hypothesis
is supported by observations of Heydorn et al. and Gregg
et al. Heydorn et al. who reported that different tissues
showed variable elimination half-lives. Gregg et al. even
showed that Pt levels in peripheral nerve tissue such as the
dorsal root ganglia, did not decay with time [28], which
was expected considering the slow regeneration of periph-
eral nerve tissue [29]. Because the rate of regeneration of
tissue decreases with age, the observation that a higher age
was associated with a longer t1/2 was in correspondence
with the hypothesis that Pt levels recovered in the plasma
represent the regeneration of tissue.
In addition to follow-up time, the cumulative dose also
appeared to be associated with plasma Pt levels, which
was expected as a higher initial Pt load will result in higher
tissue concentrations [28] and thus higher long-term
plasma Pt levels. Few other studies also suggested a corre-
lation between cumulative Pt dose and long-term plasma
or serum Pt levels [8,11].
The association between renal function and plasma Pt lev-
els was also evaluated. In a previous study it was shown
that urinary Pt concentrations of patients studied 5.3 to
16.8 years after completion of cisplatin chemotherapy,
were strongly correlated to serum concentrations suggest-
ing rate limiting release of Pt from the tissues followed by
fast renal excretion [10]. This observation implies that no
effect of renal function at follow-up on plasma Pt elimina-
tion would be expected. The renal function before start of
the treatment, however, could affect the initial elimina-
tion of Pt from pUF [30] and thus the total level of Pt accu-
mulation in the tissues. Therefore, renal function might
affect long-term plasma Pt levels. This hypothesis was in
accordance with our observation that a higher GFR at the
time of treatment was associated with lower plasma Pt lev-
els.
A similar approach counts for the administration of STS at
the time of chemotherapy. The binding of STS to cisplatin
could inactivate cisplatin resulting in a reduction of initial
Pt accumulation in tissue. Our results demonstrated that
long-term plasma Pt levels were reduced by 71% with co-
administration of STS, which is in agreement with a
reduced tissue accumulation. Although, the intra-arterial
administration of cisplatin in patients who received STS
could affect the venous plasma pharmacokinetics after
administration due to a first pass effect in tissue [31], we
do not expect that the administration route affects the
total amount of Pt bound to tissue and thus the long-term
plasma Pt levels. The first-pass extraction by the tissue
after i.a. administration might lead to an increased instan-
taneous accumulation of Pt in the tissue. This does not
increase the elimination of Pt from the body, as STS does.
In contrast, i.a. administration might increase the long-
term Pt levels because of the initial increase of Pt retention
in the tissues. A definite conclusion concerning this mat-
ter, however, cannot be drawn as there are no studies
available describing the difference between i.a. adminis-
tered equal doses of cisplatin with or without co-adminis-
tration of STS.
Although no reports have been published on the effects of
GST genotypes on Pt pharmacokinetics, GST genotypes
could, considering the detoxification mechanism for Pt
from cells [32], affect the initial Pt elimination from the
tissues and thus the long-term tissue and plasma Pt levels.
For the current study, however, no such relationship
could be established, possibly due to a low number of
patients.
Conclusion
Our data suggest that plasma Pt levels are related to fol-
low-up time, age, cumulative dose, GFR at time of treat-
ment, and STS use. Although no Pt-DNA adducts could be
detected in PBMCs, it was shown that Pt species in pUF
were still present in a reactive form. The effects of the
observed reactive species on long-term consequences of
Pt-containing chemotherapy, however, remains to be
established.
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